BAYER AND ONYX BEGIN NEXAVAR STUDY

Bayer Pharmaceuticals and Onyx Pharmaceuticals have announced the initiation of a randomized, double-blind, placebo-controlled Phase III clinical trial studying Nexavar (sorafenib) tablets administered in combination with the chemotherapeutic agents carboplatin and paclitaxel in patients with non-small cell lung cancer (NSCLC).

The multicenter study will compare Nexavar when co-administered with two chemotherapeutic agents -- carboplatin and paclitaxel -- versus carboplatin and paclitaxel alone. The study, which is expected to enroll approximately 900 patients, will assess overall survival as the primary endpoint. Secondary endpoints include progression-free survival, tumor response and safety.